1.Effect of Peritoneal Dialysis Modality on the 1-Year Rate of Decline of Residual Renal Function.
Chan Ho KIM ; Hyung Jung OH ; Mi Jung LEE ; Young Eun KWON ; Yung Ly KIM ; Ki Heon NAM ; Kyoung Sook PARK ; Seong Yeong AN ; Kwang Il KO ; Hyang Mo KOO ; Fa Mee DOH ; Seung Hyeok HAN ; Tae Hyun YOO ; Beom Seok KIM ; Shin Wook KANG ; Kyu Hun CHOI
Yonsei Medical Journal 2014;55(1):141-148
PURPOSE: The effect of different peritoneal dialysis (PD) modalities on the decline in residual renal function (RRF) is unclear due to inconsistencies among studies. In particular, the effect of automated peritoneal dialysis (APD) modalities [continuous cyclic peritoneal dialysis (CCPD) and nightly intermittent peritoneal dialysis (NIPD)] on RRF has not been examined in a large cohort. MATERIALS AND METHODS: We conducted a single-center retrospective study to investigate the association between PD modalities and decline in RRF in 142 incident PD patients [34 on CCPD, 36 on NIPD, and 72 on continuous ambulatory peritoneal dialysis (CAPD)]. RRF was measured within 2 months from PD start and at 1 year after PD initiation. RESULTS: The RRF at 1 year after PD initiation was 1.98+/-2.20 mL/min/1.73 m2 in CCPD patients and 3.63+/-3.67 mL/min/1.73 m2 in NIPD patients, which were moderately lower than 4.23+/-3.51 mL/min/1.73 m2 in CAPD patients (p=0.064). Moreover, there was no significant difference in the 1-year rate of decline of RRF between CCPD and NIPD patients, although APD patients had a faster 1-year RRF decline rate than CAPD patients (CCPD and NIPD vs. CAPD: -45.68 and -36.69 vs. 1.17%/year, p=0.045). APD was associated with a more rapid decline in RRF in patients with end-stage renal disease undergoing PD, although multivariate analysis attenuated the significance of this finding (beta=-31.50; 95% CI, -63.61 to 0.62; p=0.052). CONCLUSION: Our results suggest that CAPD might be more helpful than APD for preserving RRF during the first year of dialysis therapy, although there was no significant difference in the 1-year rate of decline of RRF between the two APD modalities.
Adult
;
Female
;
Glomerular Filtration Rate/physiology
;
Humans
;
Kidney/pathology/physiopathology
;
Kidney Failure, Chronic/*therapy
;
Male
;
Middle Aged
;
Peritoneal Dialysis/*adverse effects
;
Retrospective Studies
2.The changes in cardiac dimensions and function in patients with end stage renal disease undergoing hemodialysis.
Dong Won LEE ; Yong Beom KIM ; Seong Jae AN ; Yoo Suck JUNG ; Ihm Soo KWAK ; Yung Woo SHIN ; Ha Yeon RHA
The Korean Journal of Internal Medicine 2002;17(2):107-113
BACKGROUND: It is absolutely necessary to evaluate cardiac function on starting and during hemodialysis in patients with end stage renal disease. In this study, we tried to determinate the changes of cardiac function associated with hemodialysis. METHODS: Twenty patients with end stage renal disease, who had been in a hemodialysis program from February, 1997 to August, 1999 in Pusan National University Hospital, were enrolled. They were examined with echocardiography and gated blood pool scintigraphy on starting hemodialysis and after follow-up. The data were analyzed by paired t-test. RESULTS: The patients were 46.2 +/- 16.8 years old and male to female ratio was 8 : 12. The underlying diseases were diabetes mellitus (n=10), hypertension1), glomerulonephritis2) and others1). The duration of symptoms associated with end stage renal disease and underlying diseases was 3.4 2.6 years and the duration of hemodialysis was 13.8 7.0 months. The LVEDID, LVESID and RVC decreased significantly (-6.10, -7.80 and -20.00%, respectively, p < 0.05) with no significant changes for LAD, IVS, PWT and EF (p > 0.05). In ten cases associated with diabetes, LVEDID decreased (-7.90%, p < 0.05). In twelve cases associated with cardiac diseases, LVEDID and LVESID decreased (-8.60 and -10.50%, respectively, p < 0.05). In four cases associated with diabetes without cardiac diseases, LAD decreased (-5.10%, p 0.05) and in four cases associated with cardiac diseases without diabetes there were no significant changes in cardiac dimensions and EF. In seven cases associated with diabetes and cardiac diseases, LVEDID decreased (-10.50%, p < 0.05). The EF on gated blood pool scintigraphy decreased (-0.9%, p < 0.05) as a whole while it increased (5.90%, p < 0.05) in the cases associated with diabetes and cardiac diseases. CONCLUSION: During the early hemodialysis stage of end stage renal disease, we found a change of concentric left ventricular hypertrophy and relatively preserved left ventricular function. Furthermore, we can expect that adequate hemodialysis - with dry weight as low as possible - may prevent progression to eccentric left ventricular hypertrophy and dilated cardiomyopathy.
Adult
;
Aged
;
Cardiomyopathy, Congestive/prevention & control
;
Diabetic Nephropathies/pathology/physiopathology/therapy
;
Echocardiography
;
Female
;
Gated Blood-Pool Imaging
;
Heart/*physiopathology
;
Human
;
Hypertrophy, Left Ventricular/prevention & control
;
Kidney Failure, Chronic/pathology/*physiopathology/*therapy
;
Male
;
Middle Age
;
Myocardium/pathology
;
*Renal Dialysis
;
Ventricular Function, Left
3.Basic experimental and clinical research on peritoneal dialysis in the past 16 years.
Fuyou LIU ; Youming PENG ; Shalin ZOU ; Guanghui LING ; Jing NIE ; Wenbin TANG ; Xun ZHOU ; Shaobin DUAN ; Jun LI ; Yinghong LIU ; Hong LIU ; Fang YUAN ; Li XIAO ; Li ZHUO ; Junxiang CHEN ; Xing CHEN ; Meichu CHENG ; Jianling ZHU ; Xiaoping ZHU ; Ji' an LUO ; Min FAN ; Hao ZHANG ; Lin SUN
Journal of Central South University(Medical Sciences) 2009;34(3):269-276
To summarized the experiences from our basic experimental and clinical research on peritoneal dialysis. In the past 16 years, peritoneal fibrosis rat models and rabbit models of peritonitis were first established successfully in our laboratory in China. Peritoneal mesothelial cells were also separated and identificated. Besides, we assessed the biocompatibility of peritoneal dialysis fluid and analyzed the molecular mechanism of peritoneal mesothelial cell injury. We demonstrated the key role of transforming growth factor-beta1 (TGF-beta1), connective tissue growth factor (CTGF) and peroxisome proliferative activated receptor-gamma (PPAR-gamma) in the pathogenesis of peritoneal fibrosis, as well as their regulation of molecular mechanism. Furthermore, we transfected the plasmids encoding TGF-beta1-shRNA or pCTGF-shRNA into peritoneal cells and tissues by nanocarrier technologies. In clinical research, the positioning of peritoneal dialysis catheters, peritoneal dialysis treatment modalities and the prevention and treatment of its complications were studied. The characteristics and mechanism of solute transport in peritoneal dialysis was also explored.
Animals
;
Connective Tissue Growth Factor
;
metabolism
;
Fibrosis
;
physiopathology
;
prevention & control
;
Humans
;
Kidney Failure, Chronic
;
metabolism
;
therapy
;
Peritoneal Dialysis
;
methods
;
Peritoneal Dialysis, Continuous Ambulatory
;
adverse effects
;
Peritoneum
;
pathology
;
Rabbits
;
Rats
;
Retrospective Studies
;
Tissue Adhesions
;
physiopathology
;
prevention & control
;
Transforming Growth Factor beta
;
metabolism